Recent studies suggest that SGLT2 inhibitors may reduce the risk of urinary stone formation, demonstrating their complex pharmacological effects beyond their initial use for diabetes management, as well as their roles in HF and CKD [30,31,32,33,34,35,36,37]. Here, SLC5A2 is linked to chronic kidney disease.